Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions ...

Imaging technologies like MRI are typically used to identify the brain regions affected by the disease. The BrainSense Adaptive technology is designed for use with Medtronic’s Percept PC and RC ...

For more than ten years, Medtronic has been developing a complete, sensing-enabled DBS system leveraging exclusive BrainSense™ technology to detect, capture, and classify different brain signals ...

the largest commercial launch of brain-computer interface technology ever GALWAY, Ireland, Feb. 24, 2025 /PRNewswire(opens new window)/ -- For the one million people diagnosed with Parkinson's disease ...

The company said its U.S. rollout represents the largest-ever commercial launch of a brain-computer interface technology, with Medtronic’s BrainSense platform reading changes in a patient’s ...

Medtronic has received approval from the US Food and Drug Administration (FDA) for BrainSense, its adaptive deep brain stimulation (aDBS) therapy for patients living with Parkinson’s disease.

Medtronic plc, a Galway-headquartered global leader in healthcare technology, announced the US FDA has approval of BrainSense adaptive Deep Brain Stimulation (aDBS) and BrainSense Electrode Identifier ...

Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease. The approval is for BrainSense Adaptive deep brain stimulation (DBS)and BrainSense ...

Medtronic has received CE marks under the European Union’s Medical Device Regulation (EU MDR) for the BrainSense adaptive deep brain stimulation (aDBS) system and electrode identifier (EI ...